The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer

4.7 (511) · € 36.50 · En Stock

Frontiers TTCC-2019-02: real-world evidence of first-line

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil

Current Landscape and Future Directions of Docetaxel in Advanced

Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus

Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin

Cetuximab, docetaxel, and cisplatin as first-line treatment in

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil

Comprehensive review on how platinum- and taxane-based

Induction chemotherapy with lobaplatin and fluorouracil versus

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine